Category Archives: Immunology

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer – StreetInsider.com

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

CAMBRIDGE, England--(BUSINESS WIRE)--Mogrify Limited (Mogrify), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Dr. Louise Modis as Chief Scientific Officer, following the recent completion of a $33 million USD Series A funding. Louise is an accomplished scientific leader in therapeutic discovery and development, and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas. In her new role, Louise will lead the advancement of the Companys internal programs to help address high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.

Louise has over 20 years experience in pre-clinical and clinical therapeutic research. Formerly Vice President of Immunology Research at GlaxoSmithKline (GSK), she led the generation and advancement of a pipeline of assets from target identification through to clinical proof-of-concept studies. Her roles at GSK included sponsorship of the Immunology Network, hosting external collaborators at GSK on sabbatical to nucleate and develop novel therapeutic concepts, championing in-licensing of assets, and representing GSK on the board of Sitryx. Prior to GSK, Louise led research teams at Boehringer Ingelheim Pharmaceuticals, and Millennium Pharmaceuticals (now Takeda), where she progressed therapeutic candidates targeted at immunology, oncology, and cardiovascular indications with unmet need. Dr. Modis holds a BSc (Biotechnology) from the National University of Ireland, Galway, earned her PhD (Developmental Hematology) at EMBL, Heidelberg, Germany and completed her postdoctoral fellowship at Harvard University, Boston.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: We are delighted to welcome Louise to the Mogrify Executive Team following a global search that considered drug discovery specialists from across Europe and the United States. Louises domain expertise, intellectual curiosity and passion for developing novel modalities capable of transforming clinical outcomes for patients suffering with degenerative diseases, make her an ideal fit to lead our internal programs through to first-in-human studies.

Dr. Louise Modis, Chief Scientific Officer, Mogrify, added: I am very excited to join Mogrify and to be able to deploy its powerful cell reprogramming platform to address the most immediate challenges of developing cost-effective ex vivo cell therapies in immuno-oncology. I am particularly enthused by the Companys development of novel in vivo therapeutic modalities and the opportunity to progress a number of in vivo reprogramming therapies rapidly through development into the clinic.

For further information about Mogrifys team, please visit:

https://mogrify.co.uk/team/leadership-team/

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005528/en/

Zyme CommunicationsMichelle Ricketts, PhDTel: +44 (0)7789 053 885Email: michelle.ricketts@zymecommunications.com

Source: Mogrify Limited

See the original post:
Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer - StreetInsider.com

1700+ Graduates from Class of 2020 Expected to Return for Long-awaited In-Person Commencement Ceremony – UCF

Homecoming weekend will mean a little bit more to a special group of 1,700 Knights expected to return to campus to experience the milestone of an in-person commencement. For some, this graduation ceremony has been delayed more than a year.

Spring, Summer and Fall 2020 grads representing each of UCFs 13 colleges have registered for the ceremony, which will take place Nov. 5 at 9 a.m. at Addition Financial Arena and be livestreamed on UCFs YouTube channel.

Darin Edwards 97 10MS 11PhD who led the charge to create Modernas mRNA COVID-19 vaccine will serve as the keynote speaker for the 2020 Graduation Celebration.

In 2020, the Florida Board of Governors required all of Floridas state universities to hold virtual commencement ceremonies due to the COVID-19 pandemic. UCF conferred more than 18,000 degrees during its 2020 virtual commencement ceremonies.

During the ceremony, graduates will cross the stage during the traditional Pomp and Circumstance processional as their names are called. Each graduate is allowed up to four guests in attendance.

The deadline to participate in the Nov. 5 ceremony has passed. Participation in the ceremony is specifically for those graduates who missed in-person commencements experiences in 2020. Other graduates who would like to participate in a make-up ceremony may walk during the fall commencement ceremonies, which will be held Dec. 17-18.

Edwards is the director of immunology in the infectious disease group at Moderna, where he led the research and development on their mRNA COVID-19 vaccine. Additionally, he directs the immunology team in support of vaccine development programs and foundational research efforts, and leads work with external academic and industry collaborators including Modernas collaborative research efforts with the National Institute of Health, WHO, and Harvards pathogenesis working group.

Prior to joining Moderna in June 2019, Edwards served eight years for Sanofi Pasteur in Orlando, where he worked to develop vaccines against infectious diseases, including RSV, influenza, dengue, and yellow fever.

Edwards is a much-published researcher and academic speaker.Through his educational background at UCF, combined with his yearsof experience working on the development of next-generation vaccinetechnology, he has had the unique opportunity to make adirect and positive impact on global health.

He earned a bachelors inbiology, a masters in molecularbiology and microbiology and a doctorate inbiomolecular sciences from UCF, where he was also a Burnett Honors Scholar.

The health and well-being of all UCF graduates and their guests are the top priority of the university. Face coverings are expected while indoors for all attendees whether vaccinated or not, in accordance withthe latest CDC guidelines.

Continue reading here:
1700+ Graduates from Class of 2020 Expected to Return for Long-awaited In-Person Commencement Ceremony - UCF

Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) – DocWire News

This article was originally published here

BMJ Open. 2021 Sep 30;11(9):e047133. doi: 10.1136/bmjopen-2020-047133.

ABSTRACT

PURPOSE: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) is a prospective cohort study in South Africa investigating the association between antiretroviral therapy (ART) use, preterm delivery (PTD) and small-for-gestational age (SGA) live births. PIMS main hypotheses are that ART initiation in pregnancy and ART-induced hypertension are associated with PTD and SGA respectively and that reconstitution of cellular immune responses in women on ART from before pregnancy results in increases in PTD of GA infants.

PARTICIPANTS: Pregnant women (n=3972) aged 18 years regardless of HIV status recruited from 2015 to 2016 into the overall PIMS cohort (2517 HIV-negative, 1455 living with HIV). A nested cohort contained 551 women living with HIV who were 24 weeks GA on ultrasound: 261 initiated ART before pregnancy, 290 initiated during the pregnancy.

FINDINGS TO DATE: Women in the overall cohort were followed antenatally through to delivery using routine clinical records; further women in the nested cohort were actively followed up until 12 months post partum, with data collected on maternal health (HIV care and ART use, clinical care and intercurrent clinical history). Other procedures conducted on the nested cohort included physical examinations (anthropometry, blood pressure measurement), assessment of fetal growth (ultrasound), maternal and infant phlebotomy for storage of plasma, RNA and peripheral blood mononuclear cells, collection of delivery specimens (placenta and cord blood) and infant 12-month developmental assessment. Preliminary findings have contributed to our understanding of risk factors for adverse birth outcomes, and the relationship between pregnancy immunology, HIV/ART and adverse birth outcomes.

FUTURE PLANS: Using specimens collected from study participants living with HIV throughout pregnancy and first year of life, the PIMS provides a valuable platform for answering a variety of research questions focused on temporal changes of immunology markers in women whose immune status is altered by HIV infection, and how ART initiated during the pregnancy affects immune responses. The relationship between these immunological changes with adverse birth outcomes as well as possible longer-term impact of exposure to ART in fetal and early life will be explored. Additionally, further active and passive follow-up of mothers and their infants is planned at school-going age and beyond to chart growth, morbidity and development, as well as changes in family circumstances.

PMID:34593488 | DOI:10.1136/bmjopen-2020-047133

Go here to read the rest:
Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) - DocWire News

Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune…

Comprehensive Global Immunology Drug Market from 2021 to 2027 analysis with precise projections and predictions, as well as full research solutions for strategic decision-making, are provided by Market Research Place studies. It also has separate chapters that include the regional studies to get a picture of the markets with future opportunities followed by the estimated yearly growth during the survey period from 2021 to 2027.

The report investigates the market by examining market dynamics, market trends, current trends, issues, challenges, competition analysis, and the firms involved. The study also goes into great detail on supply and demand assessments, as well as the participation of major industry players and market share growth statistics. All of the income margins, pricing, revenue proportions, and gross margins are determined in part.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/216577/request-sample

It examines the market segments in the Immunology Drug market in depth:

The study takes into account a diverse variety of manufacturers, with business profiles of included

It provides granular analysis of the market segments of the Immunology Drug market:

The evaluation covers the major geographical areas that the industry operates in, including

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-immunology-drug-market-research-report-2021-2027-216577.html

Main Points of the Report

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketresearchplace.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketresearchplace.com

Read the rest here:
Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune...

‘Last throw of the dice’ for Covid-19, claims Professor Luke O’Neill – Dublin Live

A leading immunology expert has given hope that Covid-19 may finally be on its "last throw of the dice".

The Delta variant completely changed how the public lives with Covid-19 given its higher transmissibility compared to previous strains of the disease.

But Professor Luke O'Neill of Trinity College told Today with Claire Byrne this morning that Delta "may be as bad as it gets" with vaccines holding firm against it.

"The vaccine is holding firmly against Delta is the message," he said.

A new study shows protection from the Pfizer vaccination remains at 90% six months after the second dose is administered.

However, Professor O'Neill adopted a more cautious tone when it came to giving booster shots to the wider population.

Professor O'Neill said: "It may change when it gets to nine months out or 12 months, then that might be slightly different."

He added if there's evidence of increased risk in six months time "then you may start giving a booster - it may well become a three-shot vaccine finally".

To get the latest breaking news straight to your inbox, sign up for our free newsletter

Read more:
'Last throw of the dice' for Covid-19, claims Professor Luke O'Neill - Dublin Live

U of M research: vaccine offers greater protections for those who’ve already had COVID – MinnPost

The Star Tribunes Jeremy Olson writes: New University of Minnesota research is contesting a key argument against COVID-19 vaccination that people with prior coronavirus infections dont need further immunization to protect themselves. Comparing blood samples following COVID-19 vaccinations in 48 participants, the U researchers found that everyone gained key memory B cells capable of producing antibodies that fight off the coronavirus, but people with previous infections gained five times more of those cells. And in the world of immunology, more is better, said Marc Jenkins, a co-author and director of the Center for Immunology at the U Medical School.

WCCO-TV reports: Violence Free Minnesota released its 2020 homicide report on Friday, which analyzes relationship abuse in the state. In all, the report says that at least 30 people were killed due to intimate partner violence in 2020, and all but one of the victims identified as a woman. Of the 30 victims, 21 were killed by a current or former intimate partner, and nine victims were friends or family members attempting to intervene. Three of the victims were children.

For MPR, Mat Sepic writes: The lawyers prosecuting Kimberly Potter, the former police officer who killed Daunte Wright, are planning to introduce evidence showing that Potter was trained in the proper use of a Taser. As Potter, 49, and another Brooklyn Center officer tried to arrest Wright on a firearms warrant during a traffic stop April 11, he broke free and got back in his car. Potter is heard on video shouting Taser but instead pulls her handgun and shoots Wright in the chest. Potter is charged with first and second-degree manslaughter.

At FOX 9, Howard Thompson reports: A man is in custody after a police chase turned into a standoff with shots fired in Duluth, Minnesota on Friday. In tweets Friday evening, police say the suspect, who officers say was wanted following an attempted bank robbery and police chase, surrendered at about 8:30 p.m., hours after the incident began. According to police, the incident started at about 12:30 p.m. with a pursuit through the city and surrounding areas.

Article continues after advertisement

For MPR, Jon Collins writes: A pilot program launching Monday is aimed at freeing up Minneapolis police by using civilian city employees to enforce parking violations overnight. Parking control officers have traditionally enforced parking regulations during daylight hours and then handed duties off to the Minneapolis police for the night. Saray Garnett-Hochuli, interim director for regulatory services, said complaints about parking violations during these hours often went unaddressed because they were a low priority for police.

In the Pioneer Press, Betsy Helfand writes: A season that began with playoff aspirations will officially end with a fifth-place finish for the Twins, their first time winding up in the American League Central cellar since 2016, when they finished with the worst record in the majors. With an 11-6 loss to Kansas City on Friday night at Kauffman Stadium, the Twins (71-89) are three games behind the Royals (74-86) with two to play, locking them into fifth place in 2021 after winning division titles in each of the past two seasons.

Stephen Groves writes for the AP: South Dakota Gov. Kristi Noem on Friday defended her administrations handling of her daughters application for a real estate appraiser license, attempting to brush aside questions about a meeting she held last year that included her daughter, Kassidy Peters, and the state employee who was overseeing her application. I never once asked for special treatment for Kassidy, the Republican governor said in video posted on YouTube days after The Associated Press first reported on the meeting. The meeting happened after the Department of Labor and Regulation moved to deny Peters the license. Four months later, in November 2020, Peters received her certification as a residential appraiser, according to the department.

Here is the original post:
U of M research: vaccine offers greater protections for those who've already had COVID - MinnPost

Opinion: In reponse to Robert Wise – Northside Sun

In all my columns concerning this pandemic, I never mentioned attorney Robert Wise in any way, but he has chosen not only to attempt to insult me but even intruded on the border of slander by several not-so clever ploys. First, he searched the discredited attack professional groups who make a living attacking anyone who challenges the orthodoxy. I recognized the MO immediatelythey all use the same worn-out material. While not actually saying so, it might be construed from the way he presented it that I lost my medical license when in truth, I retired from my neurosurgical practice in 2007. When one retires it is customary to also retire ones medical license. Not mandatory, but if you never plan to return to clinical practice why continue to pay the fees each year? I am almost 76 years oldwe do retire.

There is an old saying that If you cannot answer a mans arguments, all is not lostyou can still call him vile names. Many of those attacking those of us who believe in informed consent, that is, the right of the public to know all the facts concerning a proposed treatment, think like despots in totalitarian countries, assuming that only official or state controlled information should have access to the public square. One can always tell when a groups so-called information is tainted and cannot be openly defended. The controllers of information immediately use the courts or bureaucracies to control the debate, and they resort to personal attacks. We call that dirty pool or attack journalism.

My opinion, reading Wises latest nonsense being sold as reasoned argument, is that it is a cry of desperation and frustration at being intellectually unarmed. As for my credentials, I am the associate editor-in-chief of the neuroinflammatory section of the international journal Surgical Neurology International, one of the most read international neurosurgical journal in the world. In this position, I peer review submitted articles from experts on subjects dealing with immunology, neuroinflammation and infectious diseases affecting the brain and spinal cord.

I have around 60 articles published in a variety of scientific publications, a number dealing with immunology and the effects of vaccines on the central nervous system. My articles have been cited by other scientific journal articles over 1000 times. I am cited in a number of prestigious scientific papers as well as having a textbook chapter on immunoexcitotoxicity as a major pathophysiological mechanism for chronic traumatic encephalopathy (Biomarkers for Traumatic Brain Injuries, 2012, Dambinova SA et al eds). I have published articles on the pathophysiology of vaccine damage to the developing brain, articles that are widely cited in the scientific literature. I work with some of the top experts in immunology, vaccine complications and the effects of these vaccines on the nervous system. In addition, I have a two-part article published as an extensive primer for neurologists and neurosurgeons on immunology, both acquired and innate, which was reviewed by one of the top experts in immunology at UCLA Medical Center.

I have written six books on medical subjects and contributed chapters in four textbooks as well. What I find strange is that our illustrious attorney has, as far as I know, published nothing in the scientific literature on any of these subjects. All he can seem to do is tell emotional just-so stories and quote medical bureaucracies, such as the CDC and WHO, that are making millions off these and other vaccines. Both these bureaucracies are known to be corrupt to the core. The CDC has never treated a single patient for a covid-19 infection, yet they designed the protocol for most hospitals, that is generally rigidly enforced. Their protocol, in my opinion and others, was and continues to be responsible for a large percentage of the covid deaths in these hospitals.

The CDC also established the insane idea that infected people should stay at home, use no early treatments, until they were so sick, they require hospital or even ICU treatment. To compound this, they told people they should just take Tylenol and drink lots of liquids. Tylenol is a very dangerous drug and is responsible for a high percentage of serious complications seen in our hospitals. Each year we have over 700 deaths from Tylenol complications and during that same period there were only 2 deaths from Ivermectin. Every country that has initiated, as state policy, the use of Ivermectin has seen a dramatic and rapid drop in hospitalization and deaths. Some 27 randomized clinical studies from all over the world confirm that Ivermectin is very safe and dramatically reduces the death rate associated with this infection. Other early treatments, according to carefully controlled studies, have reduce death rates by as much as 80%, which if initiated by all states would have saved tens of thousands of lives. Instead, medical societies threaten our doctors with a loss of their license should they even speak anything but the incessant propaganda by the CDC and other medical bureaucracies. It is this massive control of medical information that is responsible, in my opinion and others, for the mass death associated with this virus.

Keep in mind that we would not be suffering from this never-ending pandemic had not Dr. Fauci, along with his cohorts, not supplied the Chinese communist bioweapons lab in Wuhan, China with millions of dollars in aid, as well as supplying critical information on viral gain-of-function from Dr. Ralph Barik in Chapel Hill North, Carolina.

Our Wise loves to quote stories of individuals who have died because they were unvaccinated, but he quotes none of the thousands of stories of those whose lives have been destroyed or ended by the vaccines, including the loss of a significant number of babies of pregnant women. In fact, according to an analysis of the data from the VAERS government reporting system, 4,524 cases of vaccine-linked myocarditis and pericarditis were reported from 9/3/2021. Of these, 385 occurred in children age 12 to 17 years of age. The figure continues to rise rapidly. Incredibly, 86% of healthy vaccinated boys required hospitalization. Those childrens lives have been ruined forever. They may never play sports, hike strenuous trails, or look forward to any semblance of a normal life, rather they can look forward to a life of cardiac incapacity of a progressive nature. All this over a vaccine that has been shown not to protect, was poorly tested before being released and used among an age group that was experiencing virtually no risk from this virus.

In my opinion and others, these children were the victims of the fear mongering and lying propaganda by the government agencies, medical associations, and the pharmaceutical-controlled media. As far as the so-called covid cases, there is no adequate testing to determine if a person has a clinical infection since the PCR test has been discontinued because it could not distinguish between the influenza virus and Covid-19. As we have seen all along, these so-called authorities are counting everything as being a covid hospital admission and/or death. As for the unvaccinated being the primary source of the viral transmission, we have learned that these authorities have a very interesting definition of being unvaccinatedeven a person who has had both doses of the vaccine, if they are admitted or die less than 14 days from the second dose they are labeledunvaccinated. This deception is used by all these vaccine promoting agencies.

I agree with a number of experts in this field, that it is the vaccinated that are primarily spreading this new virus variant, not the unvaccinated. Vaccinated parents are exposing their children in their home for very long periods. Fauci even admitted that the viral concentration in the nasopharynx of the vaccinated was very high and could be transmitted. Now we have most medical personnel acting as viral carriers and transmitters to their patients as they have been forced by hospitals and medical centers to be vaccinated.

Russell L. Blaylock, M.D.

See the original post here:
Opinion: In reponse to Robert Wise - Northside Sun

AbbVie to Host Third-Quarter 2021 Earnings Conference Call – WITN

Published: Oct. 5, 2021 at 8:00 AM EDT|Updated: 7 hours ago

NORTH CHICAGO, Ill., Oct. 5, 2021 /PRNewswire/ --AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvieon Twitter, Facebook, Instagram, YouTubeand LinkedIn.

View original content:

SOURCE AbbVie

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Go here to read the rest:
AbbVie to Host Third-Quarter 2021 Earnings Conference Call - WITN

MCB Assistant Professor Cluster Hire-Neuroimmunology job with Montana State University | 388051 – The Chronicle of Higher Education

Three Faculty Positions in the Department ofMicrobiology & Cell Biology at Montana StateUniversity

This is where research and discovery happen. Located in theheart of the Rocky Mountains, Bozeman, Montana offers a healthylifestyle and a world class research university that facilitatesinnovation and scholarship. The Department of Microbiology &Cell Biology at Montana State University (MSU) invites applicationsfor three tenure track faculty positions in the field ofNeuroimmunology. This cluster hire aims to attract a diverse cohortof exceptional individuals that will establish nationallyrecognized, and externally funded research programs that useinnovative new methods to interrogate dynamic interactions at theinterface of Neurology and Immunology. Areas of interest include,but are not limited to, fundamental and applied biology,immunology, neurology, pathology, psychiatry, parasitology, aging,structural biology, and virology. Successful applicants willintegrate their research programs with undergraduate and graduatestudent instruction and participate in professional serviceactivities. We are particularly interested in individuals whosework complements and strengthens the research interestsofMSUfaculty, including those focused on neurology,developmental biology, immunology, microbial physiology andecology, molecular evolution, virology, biomedical microbiology,environmental health, structural biology, and host-pathogeninteractions. The Department of Microbiology & Cell Biologyoffers a dynamic research and teaching environment withstate-of-the-art facilities for infectious disease (e.g., BSL3),flow cytometry, light and cryo-electron microscopy, histology, andsmall and large animal research. The University supportscomprehensive cores in metabolomics, proteomics, imaging,structural biology, and genomics/bioinformatics. This position issupported by a competitive institutional salary, a generousstart-up package, and state-of-the-art research facilities. The jobdescription and application materials are available online(https://jobs.montana.edu/postings/25947).

Screening of applications will begin on October 15th, 2021 andscreening will continue until an adequate applicant pool has beenestablished. Montana State University values diverse perspectivesand is committed to continually supporting, promoting and buildingan inclusive and culturally diverse campusenvironment.MSUrecognizes the importance of work-lifeintegration and strives to be responsive to the needs of dualcareer couples. Equal Opportunity Employer, Veterans/Disabled

Please contact Kelley Kane (kelleykane@montana.edu) for moreinformation.

Read the rest here:
MCB Assistant Professor Cluster Hire-Neuroimmunology job with Montana State University | 388051 - The Chronicle of Higher Education

VBI Vaccines to Participate in Upcoming Investor Conferences – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that members of the management team will participate in analyst-led fireside chats at the following upcoming investor conferences:

Guggenheim 2nd Annual Vaccines & Infectious Disease ConferenceDiscussion to be held with Evan Wang Equity Research Senior Associate

H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) ConferenceDiscussion to be held with Patrick Trucchio Managing Director, Senior Healthcare Analyst

Live webcasts of the presentations will also be available on the Investors page of VBIs website at: https://www.vbivaccines.com/investors/events-and-presentations/. A replay of each webcast will be archived on the Companys website following the presentation.

About VBI Vaccines Inc.

VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (VLPs), including a proprietary enveloped VLP (eVLP) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, COVID-19 and coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). The Company cautions that such statements involve risks and uncertainties that may materially affect the Companys results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Companys ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Companys products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Companys filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 2, 2021, and filed with the Canadian security authorities at sedar.com on March 2, 2021, as may be supplemented or amended by the Companys Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

Excerpt from:
VBI Vaccines to Participate in Upcoming Investor Conferences - Business Wire